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 Low-dose ionizing radiation (LDR) may lead to suppression of smoking-related lung
cancer. We examined the effects of a known cigarette smoke carcinogen Benzo[a]pyrene
(B[a]P) alone or in combination with fractionated low-dose gamma radiation (60 – 600
mGy total dose) on the induction of lung neoplasms in the A/J mouse. Our results show
that 600 mGy of gamma radiation delivered in six biweekly fractions of 100 mGy starting
1 month after B[a]P injection significantly inhibits the development of lung adenomas per
animal induced by B[a]P. Our data also indicated that the six biweekly doses suppressed
the occurrence of spontaneous hyperplastic foci in the lung, although this suppression
failed to reach statistical significance when analyzed as average foci per lung possibly relat-
ed to the small sample sizes used for the control and test groups. 
KEY TERMS: Low-dose gamma-radiation, Benzo[a]pyrene, lung cancer 
INTRODUCTION 
Lung cancer is the leading cause of cancer mortality in both men and
women in the United States and will soon reach epidemic proportion
worldwide (American Cancer Society, 2012). Thus, lung cancer preven-
tion is currently an active research area (Belinsky et al. 2003; Lyon et al.
2009). The most important risk factor for lung cancer is tobacco smoking
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(Sanders and Scott 2008); it is estimated to account for up to 90% of lung
cancer risk in men and up to 80% in women (Walser et al. 2008).
Cigarette smoke contains approximately 5000 reactive chemical com-
pounds and carcinogens that can lead to the development of lung cancer
by damaging DNA and inducing inflammation through the recruitment
of inflammatory cells (Yao and Rahman 2009). One of these compounds
is Benzo[a]pyrene (B[a]P), a polycyclic aromatic hydrocarbon (PAH).
Metabolites of B[a]P (e.g. benzo[a]pyrenediolexposide, BPDE) are
mutagenic and carcinogenic. B[a]P causes DNA damage in lung cells
consistent with DNA damage observed in malignant lung cancers
(Denissenko et al. 1996), and its metabolites elicit a number of toxic
effects in target cells such as DNA adduct formation, cytotoxicity of lym-
phocytes, and production of proinflammatory mediators such as certain
cytokines (Wojdani et al. 1984; Umannova, et al. 2008). Studies conduct-
ed at our Institute have revealed an important role of epigenetic changes
caused by BPDE exposure that are associated with neoplastic transforma-
tion of human lung epithelial cells and presumably also lung cancer
development (Tellez et al. 2011). 
The A/J mouse strain because of its known susceptibility to lung
tumor induction by PAHs such as B[a]P, is commonly used to study lung
cancer development after carcinogen exposure (Hecht et al. 1994;
Malkinson 1992). In addition, the time course for development and pro-
gression of lung cancer (hyperplastic foci progressing to adenoma and
finally carcinoma) can be easily quantified (Lyon et al. 2009). 
Although it is common knowledge that exposure to very high doses
of radiation can induce cancer; a correlation between low doses of radia-
tion and lung cancer has yet to be demonstrated. Recently scientists have
shown that low-dose radiation can yield beneficial biological effects sug-
gesting the potential of using low doses of radiation to combat cancer for-
mation and reduce tumor prevalence and metastasis (Sakamoto et al.
1997). Researchers have investigated the effects of low-dose radiation,
given as a single dose or fractionated or protracted over time, with regard
to altering cancer development or resolution while others have focused
on the effects of low-dose radiation on the systemic immune system (Liu
2003, 2007; Sakai et al. 2003; Sakai 2006; Thompson et al. 2008;
Nowosielska 2010). The purpose of this study was to examine the effect
of a known cigarette smoke carcinogen, alone or delivered in combina-
tion with low doses of low linear-energy-transfer (LET) gamma radiation,
on the development of lung cancer in the A/J mouse. Our hypothesis is
that low-dose gamma rays protect from B[a]P-induced lung cancer. In
testing this hypothesis, we investigated the development of lung carcino-
genesis 46 weeks after treatment of mice with B[a]P and the ability of
fractionated gamma radiation (60 – 600 mGy total dose) to suppress can-
cer development. 
Low dose radiation inhibits lung adenoma
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MATERIALS AND METHODS 
Animals: 
Female, 10 week-old, A/J mice purchased from Jackson Laboratories
(Bar Harbor, ME), were separated into the following groups: B[a]P only,
B[a]P + radiation, radiation only, and age-matched unirradiated, untreat-
ed controls for a 46 week carcinogenesis experiment (n= 8-18 per group).
At 46 weeks, mice were humanely euthanized by i.p. injection of a lethal
dose of Euthasol. 
Chemicals: 
B[a]P (Sigma), at a concentration of 100 mg/kg body weight, was dis-
solved in 0.2 ml of tricaprylin (Glyceryltrioctanoate, Sigma) vehicle prior
to interperitoneal (i.p.) injection. 
Irradiation:
Mice were exposed to six biweekly whole body irradiations (WBI) at a
dose rate of 1.07 mGy/s (10 mGy target dose) or 1.33 mGy/s (100 mGy
target dose) from the Gammacell 1000 irradiator (137Cs source) (Best
Theratronics, Ontario, CA) for a total dose of 60 and 600 mGy, respec-
tively. To achieve low doses, mice were exposed individually in polypropy-
lene tubes set inside a stainless steel sample canister lined with lead foil
(7.4 mm thickness). Experimental doses received were confirmed by
nanoDots (Optically Stimulated Luminescence Technology, 1 cm2,
Landauer, Inc., Glenwood, IL) adhered to the outside of the tubes con-
taining the mice. Initial dosimetry was performed using nanoDots insert-
ed into the chests of mouse carcasses. 
Histology 
To estimate tumor burden, gross lung tumors were counted at
necropsy. Lungs were inflated with neutral buffered formalin at a con-
stant hydrostatic pressure of 25 cm for 6 hours and fixed further by
immersion in formalin for >48 hours. Left lung lobes were systematically
trimmed in a dorsoventral-transverse direction at 3-4 mm intervals with
the first slice randomly positioned within the cranial 4 mm of tissue to
yield 3-5 slices per lobe. A single slice along the axial airway of each of the
right lung lobes was also made. Trimmed tissue was histoprocessed rou-
tinely, and 5 µm-thick paraffin sections were mounted and stained with
hematoxylin and eosin for light-microscopic identification and enumera-
tion of hyperplastic foci, adenomas, and carcinomas. 
V. R. Bruce and others
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Statistical Analyses 
Tumor counts are given as means ± standard error (SE). Comparisons
between groups were performed using the Wilcoxon Rank Sum Test
except where otherwise stated. 
RESULTS 
Repeated 100 mGy gamma irradiation in B[a]P treated mice suppresses
adenoma development 
Various groups have previously demonstrated that animals exposed to
single or fractionated low doses of X-rays or gamma-rays exhibit an atten-
uated growth of implanted cancerous tumors, and lung metastases are
reduced when animals are exposed to radiation prior to inoculation with
tumor cells (Hosoi and Sakamoto 1993; Cai 1999; Cheda et al. 2004;
Nowosielska 2010). In order to ascertain whether low dose radiation
could also inhibit lung carcinogenesis initiated by a PAH contained in cig-
arette smoke, we investigated the potential for suppression of cancer pro-
gression of B[a]P-induced lung tumors in mice exposed to repeated low
doses of gamma radiation (Figure 1). 
As expected, B[a]P treated mice exhibited a significantly higher num-
ber of lesions compared to control mice or mice receiving radiation only
(p < .05, Figure 2A). The tumors observed grossly represented larger
hyperplastic foci, adenomas, and carcinomas as well as non-proliferative
lesions, such as inflammatory or fibrotic or non-lesions: multifocal pallor,
atelectasis, and/or hyperinflation. These observations were proportional
to those performed by histological analysis. In each B[a]P treated group,
the number of hyperplastic foci greatly exceeded adenomas which in
Low dose radiation inhibits lung adenoma
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FIGURE 1. Study design. Mice were given a single dose of B[a]P four weeks prior to exposure to
gamma radiation. Fractionated whole-body gamma-ray doses of 10 mGy or 100 mGy were then given
once every 2 weeks until week 14 post-B[a]P injection for cumulative dose of 60 mGy and 600 mGy,
respectively. At 46 weeks, lungs were harvested and lesions were enumerated grossly. In addition,
lungs were fixed and tissue sections were prepared for histological examination. 
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turn exceeded carcinomas representing the natural progression of lung
cancer (Figure 2B). In contrast, exposure of B[a]P treated mice to six
fractions of 100 mGy doses of gamma radiation (600 mGy total) was asso-
ciated with a significant reduction of adenomas compared to B[a]P alone
(p = .04). Interestingly, as indicated in Table 1, a single histoproliferative
lesion (hyperplastic focus) was found in 33 ± 11% of mice in the 600 mGy
radiation group whereas 63 ± 17% of the age-matched, untreated control
group had such a lesion (n = 8); however, further testing is needed to con-
firm this finding as the small group size of the age matched control mice
did not allow for statistical significance to be achieved when evaluated on
V. R. Bruce and others
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FIGURE 2. Lung tumors from mice injected i.p. with B[a]P four weeks prior to repeated irradiations
with 10, and 100 mGy gamma-rays were grossly counted upon necropsy at 46 weeks post injection and
histologically verified as proliferative lesions (A). Proliferative lesions (tumors) were further classified
as hyperplastic foci, adenomas, or carcinomas (B). Mean values ± SE obtained from a single experi-
ment is presented. Each experimental group contained 15-18 mice (n = 15-18), control group con-
tained 8 mice (n = 8). Experimental groups are as described in materials and methods section. ND =
not detected; * = p < 0.05 with the indicated groups being significantly different than each other on
the same day of analysis. 
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the basis of average foci per animal (p = .18). A more detailed analysis of
these data (Scott et al. 2012) in the context of the hormetic relative risk
(HRR) model (Scott et al. 2009; Scott 2011) demonstrated a significant
gamma-ray protective effect against spontaneous hyerplastic foci. No ade-
nomas or carcinomas were detected in the untreated control group or
the group treated with six fractions of 100 mGy dose (Table 1). 
We investigated the distribution of lung tumors (adenomas and car-
cinomas only) by exposure group. Our previously introduced HRR model
incorporates a protection factor (PROFAC), which is the population aver-
age of individual-specific protection factors, profac, against lung tumor
formation given that radiation has activated the body’s natural anticancer
mechanisms. The parameter PROFAC represents the on-average proba-
bility of lung tumor prevention when natural protection mechanisms
have been activated in every individual (Scott et al. 2009; Scott 2011).
With the HRR model, lung cancer relative risk (RR) is given by RR = 1-
B(x)PROFAC, where the benefit function B(x) represents the probability
that the body’s natural defenses are activated by a low dose x of radiation. 
To characterize the level of protection against B[a]P-induced lung
tumors that is associated with n gamma-ray fractions, we introduce the dif-
ferential protection factor, PROFAC{N+}, for protecting from cases of N or
more lung tumors. Thus, PROFAC{1+} applies to protection from 1 or
more lung tumors. PROFAC{2+} applies to protecting from 2 or more lung
Low dose radiation inhibits lung adenoma
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TABLE 1. Tumor Incidence (% of mice with the indicated lesions) and standard errora
No. % Mice with 1 or more % Mice with 1 % Mice with 1 
Group Mice Hyperplastic focus or more Adenoma or more Carcinoma
Control 8 62.5±17.1 0.0 0.0
100 mGy 18 33.3±11.1 0.0 0.0
B[a]P 12 91.7±8.0 75.0±12.5 41.7±14.2
B[a]P + 10 mGy 15 100.0 86.7±8.8 46.7±12.9
B[a]P + 100 mGy 14 92.9±6.9 57.1±13.2 50.0±13.4
aStandard error calculated assuming a binomial distribution of lesions
TABLE 2. PROFAC {N+} estimates for suppression of N or more B[a]P-induced adenomas via six bi-
weekly 100-mGy, gamma-ray fractions to female A/J mice
“N ” PROFAC{N+} Standard Error Significantly > 0?
1 0.24 0.23 no
2 0.76 0.17 yesb
3 >0.79a <0.23a yesb
aBased on subjectively assigning 1 case among 14 animals when actually none had 3 or more ade-
nomas per lung. 
bBased on PROFAC{N+} minus 2 standard errors being > 0. 
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tumors, etc. Table 2 shows results obtained for PROFAC{1+}, PROFAC{2+},
and PROFAC{3+} for protection from B[a]P-induced lung adenomas by
six fractions of 100 mGy gamma-rays. In each case B(x) was assumed to be
1 (e.g., protective mechanisms activated in each animal). Where values of
PROFAC{N+} minus two standard errors was > 0, the PROFAC value report-
ed was considered significantly > 0 (interpreted to indicate a significant
protective effect). Thus, only protection against 2 or more and against 3
or more adenomas per animal were considered significant ( p < .05).
There was no indication of a gamma-ray protective effect by the six frac-
tions of 10 mGy dose from adenomas or carcinomas (Figures 3 and 4). 
DISCUSSION 
As expected, B[a]P and/or specific metabolites (e.g., BPDE) induced
lung cancer in this study detected as hyperplastic lesions, adenomas, and
carcinomas. In contrast, mice exposed to radiation alone and unexposed
control mice developed no adenomas or carcinomas that would indicate
a progression to a more malignant phenotype. Treatment with six frac-
tions of 10 mGy gamma irradiation did not result in a reduction of B[a]P-
induced hyperplastic foci, adenomas, or carcinomas. The six fractions of
10 mGy gamma rays also did not alter the distribution of the tumors per
mouse from what was found for the B[a]P-only exposure. However, repet-
itive exposure to six fractions of 100 mGy gamma radiation reduced the
number of adenomas in B[a]P treated mice. Seventy-five ± 13% of B[a]P
treated mice developed one or more adenomas compared to 57.1 ± 13%
V. R. Bruce and others
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FIGURE 3. Frequency distribution of adenomas per mouse for the B[a]P-exposure-only group
(BaP), for the group exposed to B[a]P and 10-mGy gamma-ray fractions (BaP_10), and for the group
exposed to B[a]P and 100-mGy gamma-ray fractions (BaP_100). 
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when six fractions of 100 mGy gamma rays were administered (fraction-
ated) in addition to B[a]P (Table 1). 
When investigating the distribution of B[a]P-induced lung adenomas
we found a clear beneficial effect of the six fractions of 100 mGy gamma-
ray exposure related to reducing the multiplicity of these lesions (3 or
more) in the mouse lung. The lack of a gamma-ray protective effect
against carcinomas may relate to the 46 week follow-up time used in the
study design. We cannot rule out the possible occurrence of a protective
effect against carcinomas for much longer follow-up times. 
As a result of low-dose, gamma-ray exposure, spontaneous hyperplas-
tic foci prevalence was reduced from non-irradiated controls from 0.63 to
0.33 (Figure 2B, Table 1), although not statistically significant due to the
small sample sizes used. This finding is currently under further investiga-
tion. Interestingly, a reduction in spontaneous adenoma formation (PRO-
FAC{1+}= 0.209 to 0.321) was observed in RFMf/Un mice when subjected
to single whole-body doses of gamma radiation ranging from 100 up to
1500 mGy (Ullrich and Storer 1979). In humans, long-term residential
radon exposure has been associated with a reduction rather than an
increase in sporadic lung cancers for a range of average radon levels
(Cohen 1997, Thompson et al. 2008, Scott 2011). A PROFAC{1+} > 0.5 has
been implicated for the population studied by Thompson et al. in their
2008 paper (Scott 2011). Previously, protective effects of protracted, low-
dose, low-LET gamma radiation has also been shown against high-LET,
alpha-radiation-induced lung cancer in rats (Scott et al. 2008). A gamma-
ray PROFAC{1+} close to 1 was reported for preventing lung tumor cases
Low dose radiation inhibits lung adenoma
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FIGURE 4. Frequency distribution of carcinomas per mouse for the B[a]P-exposure-only group
(BaP), for the group exposed to B[a]P and 10-mGy gamma-ray fractions (BaP_10), and for the group
exposed to B[a]P and 100-mGy gamma-ray fractions (BaP_100).
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in rats exposed to low doses (< 200 mGy) of highly-damaging alpha radi-
ation where not more than 1 alpha-radiation-induced lung tumor per ani-
mal or not more than 1 spontaneous lung tumor per animal was expect-
ed (Scott et al. 2008; Sanders 2012). In contrast, low-dose gamma rays did
not protect (PROFAC{1+} = 0) from lung tumor induction (one or more
per animal) by very high doses (> 5000 mGy) of alpha radiation where
multiple tumors per animal may have occurred among long-term sur-
vivors because of immune system suppression (Scott et al. 2009). The data
were not analyzed to see if low dose gamma rays protected from multiple
tumors per animal. Gamma-ray protection (PROFAC{1+} > 0.8) against
alpha-radiation-induced (from inhaled plutonium-239) and smoking-
related lung tumors has also been reported for humans (Scott 2007; Scott
et al. 2009). The indicated data relate to chronic exposure of the lung at
low rates over many years to both alpha and gamma radiations. 
B[a]P primarily targets the lung when administered i.p., however we
also observed lesions not of pulmonary origin. Seven out of 77 total mice
were found to have lesions (hyperplasias, adenomas, carcinomas, or in
combination) in tissues of the stomach, pancreas, and ovaries. These
observations are consistent with those previously documented in which
B[a]P induced injection site tumors and tumors in the abdomen and pan-
creas of mice injected i.p. (Hecht et al. 1994, Balansky et al. 2006). As
there were so few mice observed to have these lesions, no analysis was per-
formed to examine the effect of radiation. 
In conclusion, results from this study suggests that six fractions of 100
mGy but not 10 mGy gamma radiation significantly reduces the multi-
plicity of adenomas but not carcinomas induced by B[a]P. Although not
statistically significant, radiation also appears to decrease the number of
cases of spontaneous hyperplastic foci by a similar degree as was reported
by other researchers for gamma-ray prevention of cases of spontaneous
lung cancer in mice (Ullrich and Storer, 1979). The mechanisms behind
this phenomenon have yet to be fully elucidated, although there is grow-
ing evidence for a hierarchy of protective mechanisms being involved
(Scott et al. 2009). Taken together, these findings support the hypothesis
that low-LET radiation (e.g., gamma rays) given at low doses and dose
rates can prevent lung cancer induction by agents such as cigarette smoke
carcinogens. 
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